# PANDORE (NCT03212651)

> Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03212651
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Conditions: Bladder Cancer
- Interventions: Pembrolizumab
- Enrollment: 41
- Primary outcome: Pathologic complete response rate

## Indexed commentary on PANDORE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pandore-nct03212651